Newly released from OZ Biosciences
NanOZ-LNP/mRNA(OVA) has been designed to produce high expression level of Ovalbumin protein which is commonly used antigen for immunization and biochemical studies and also an established model allergen for airway hyper-responsiveness.
Ready-to-use stabilized NanOZ LNP-mRNA(OVA).
mRNA encoding Ovalbumin protein formulated in Lipid Nanoparticle.
Concentration: 0.1 mg/mL RNA in LNPs in PBS with 5% sucrose.
Lipid Nanoparticles (LNPs) represent the most effective and safe delivery systems for the translational success of nucleic acid drugs.
NanOZ LNP-RNA is designed to not only protect RNA from degradation, but also facilitate intracellular uptake and thus potentiate its efficacy.
Our delivery systems are produced through microfluidic technology resulting in monodisperse NanOZ LNP-RNA with narrow size distribution and high encapsulation efficiency (>85%). OZ Biosciences developed optimized NanOZ LNPs-RNA(OVA) to improve stability and performance.
- LNP10500mRNA41: 0,5mL (2*250μL) of LNP-mRNA, (100μg/mL of 5moU OVA mRNA).
- LNP11000mRNA41: 1mL (4*250μL) of LNP-mRNA, (100μg/mL of 5moU OVA mRNA).
- LNP15000mRNA41: 5mL (10*500μL) of LNP-mRNA, (100μg/mL of 5moU OVA mRNA).
NanOZ LNP-RNA must be stored at -80°C. We recommend to minimize freeze-thaw cycles to preserve LNPs integrity.